Developing your OTC business
PRODUCT INNOVATIONS IN
red otc development creates innovative and highly competitive over-the-counter (OTC) pharmacy products as a partner of the European consumer healthcare industry. We offer these OTC products in a ready-to-market approach, completing all the necessary steps to create new, value-added medicines, medical devices and related products.
We carry out market research, cost-effective technical and regulatory realisation and clinical trials. The resulting attracting OTC products are offered to our international clients in the consumer healthcare industry that bring in their individual strategies and specialist knowledge to launch and successfully market each product.
What red otc development can do for you
We understand the preferences of healthcare consumers perfectly. Moreover, we help the OTC industry serve consumers' individual needs.
It is our business to develop, register and offer competitive and innovative OTC products for the consumer healthcare industry. To achieve optimum results in our development projects, we regularly utilise competent technology and cooperate with competitive manufacturing partners and with research and regulatory partners. Some projects are even developed exclusively in co-operation with marketing/sales partners. The flexibility in co-operation models enables us to offer, in a rather efficient and cost-effective manner, tailor-made solutions for all partners and clients that are looking to gain access to new OTC medicines, medical devices and related products.
Are you a marketing and sales company in the consumer healthcare market that is looking to expand your business with a new OTC product, marketing rights, and/or marketing authorisation?
Products for Licensing
We offer a broad line of consumer healthcare products ready for registration and commercial launch in the EU. Currently, these OTC products are available:
We are currently developing new attractive consumer healthcare products targeting the OTC and self-medication market in the following therapeutic areas:
Superiority of ODFs compared to syrups
The results of the latest clinical study by Klingmann et. al. show that orodispersible films (ODFs) are the preferred dosage format of young children compared to syrups (https://doi.org/10.1016/j.ejpb.2020.03.018). Thus, further evidence was found for Ivy ODF being the ideal dosage format for children. We are happy to share further information about the our product upon your request.
Natural medicine with modern twist
Following the success of our Ivy orodispersible thin films we proudly announce that the dossier of our PelaMelt® is ready-to-file including ICH stability data of 6 month currently. This unique and innovative licensing opportunity offers a pleasant taste (strawberry-milk) and an attractive indication in the Cough&Cold segment. Get in contact with us to obtain further information about the product!
Ivy ODF awarded with two prices
The `Best in pharmacy Awards´ committee has awarded Ivy ODF with two senior prices. Our Greek cooperation partner and we are happy to announce that the Ivy ODF won the Gold prize for the most innovative product in pharmacies and the Silver pize in the category `Best package design in pharmacies´. Please contact us for further information or click here
Sisymbrium – Ready to file
The development phase of the Sisymbrium pastilles has ended successfully. The dossier of herbal flavor is compiled and include ICH stability data of 9 month currently. The discussions with intereseted parties will finish soon. This might be the last chance for your company to obtain licensing rights for your home territory - some European countries are still available. Please contact us to check the availability of licensing rights for your territory.
PelaLiquid® - First registration procedure running
After an in-depth review of the PelaLiquid® dossier via our web-based secured data room, the first licensing partner has judged the PelaLiquid® dossier as suitable for filing. The Health Authority of the reference member state has validated the documents filed already, thus the decentralized procedure in Eastern Europe has officially started. Please contact us to check the availability of licensing rights for your territory.
red otc development GmbH
Phone: +49 251 60935 710
Fax: +49 251 60935 711
For more information on our self-medication product developments, contact us firstname.lastname@example.org
Dr. Annemarie Dengler is a pharmcist and your contact for more information on the self-medication market EU wide. Dr. Fabian Galla is an analytical chemist and responsible for new development projects. Dr. Emrah Yildir is a chemical engineer and supports the team with his expertise during the pharmaco-technical development phases.
Dr. Fabian Galla
Manager Business Development
Phone: +49 251 60935 720
Mobile: +49 170 3161544
Dr. Annemarie Dengler
Director Business Development
Phone: +49 251 60935 720
Mobile: +49 151 62649893